cytarabine has been researched along with azd 6244 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Ikezoe, T; Nishioka, C; Yang, J; Yokoyama, A | 1 |
2 other study(ies) available for cytarabine and azd 6244
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells.
Topics: Apoptosis; Benzimidazoles; Cell Cycle; Cell Cycle Proteins; Cell Differentiation; Cell Proliferation; Cytarabine; DNA Damage; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Leukemic; Histones; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases | 2009 |